OC
EW icon

Oarsman Capital’s Edwards Lifesciences EW Stock Holding History

Oarsman Capital’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,505
Closed -$185K – 441
2024
Q4 		$185K Hold
2,505
– – 0.03% 242
2024
Q3 		$165K Sell
2,505
-2,316
-48% -$168K 0.03% 268
2024
Q2 		$445K Hold
4,821
– – 0.1% 136
2024
Q1 		$461K Buy
4,821
+314
+7% +$26.4K 0.11% 132
2023
Q4 		$344K Buy
+4,507
New +$314K 0.09% 155

Other funds holding EW

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Oarsman Capital's EW Position: Q1 2025 in Review

Oarsman Capital sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 2,505 shares — an estimated $185K sold.

Oarsman Capital first reported a position in EW in Q4 2023 and held it in 5 quarters. The position peaked at $461K in Q1 2024. 1,207 funds tracked by Wall St. Rank hold EW as of Q1 2025.

  • Oarsman Capital reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
  • Oarsman Capital sold 2,505 Edwards Lifesciences shares in Q1 2025, an estimated $185K.
  • Oarsman Capital first reported a position in Edwards Lifesciences in Q4 2023 and held it in 5 quarters.
  • Oarsman Capital's Edwards Lifesciences position peaked at $461K in Q1 2024.
  • 1,207 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.

Based on Oarsman Capital's 13F filing for Q1 2025, filed 14 May 2025.